Copyright
©The Author(s) 2018.
World J Gastroenterol. Oct 28, 2018; 24(40): 4596-4605
Published online Oct 28, 2018. doi: 10.3748/wjg.v24.i40.4596
Published online Oct 28, 2018. doi: 10.3748/wjg.v24.i40.4596
Factor | Eradication rate | P value1 | Multivariate2 | ||
n/N (%) | OR (95%CI) | P value | |||
Age (yr) | < 60 | 781/827 (94.4) | 0.96 | - | - |
≥ 60 | 156/165 (94.5) | ||||
Gender | Male | 469/501 (93.6) | 0.24 | - | - |
Female | 468/491 (95.3) | ||||
Education2 | < 7 yr | 150/164 (91.5) | 0.29 | - | - |
7-9 yr | 237/249 (95.2) | ||||
10-12 yr | 187/197 (94.9) | ||||
13-16 yr | 219/229 (95.6) | ||||
> 16 yr | 20/20 (100) | ||||
Number of previous H. pylori treatment(s) | None | 800/842 (95.0) | 0.002 | Reference | - |
One | 119/127 (93.7) | 1.2 (0.5-2.7) | 0.73 | ||
Two or more | 18/23 (78.3) | 7.4 (2.2-24.9) | 0.001 | ||
Diagnosis | Functional dyspepsia | 453/478 (94.8) | 0.49 | - | - |
Peptic ulcers | 245/259 (94.6) | ||||
Erosive esophagitis | 67/69 (97.1) | ||||
Other sources of upper GI bleeding | 4/5 (80.0) | ||||
Gastric neoplasm | 6/6 (100.0) | ||||
Asymptomatic gastritis | 68/75 (90.7) | ||||
13C-UBT positive during health checkup | 94/100 (94.0) | ||||
PPI type | Esomeprazole | 253/264 (95.8) | 0.42 | - | - |
Rabeprazole | 209/224 (93.3) | ||||
Pantoprazole | 408/435 (93.8) | ||||
Other PPIs | 67/69 (97.1) | ||||
Bismuth | 400 mg per day | 204/213 (95.8) | 0.4 | - | - |
600 mg per day | 371/391 (94.9) | ||||
800 mg per day | 362/388 (93.3) | ||||
Duration of regimen | 10 d | 19/21 (90.5) | 0.33 | - | - |
14 d | 918/971 (94.5) | ||||
Adherence2 | Took 80% medicine or more | 782/819 (95.5) | < 0.001 | Reference | - |
Took less than 80% medicine | 31/40 (77.5) | 6.7 (2.8-15.8) | < 0.001 | ||
Smoking2 | Non-smoker | 631/660 (95.6) | 0.004 | Reference | - |
Abstinence during therapy | 77/80 (96.3) | 0.7 (0.2-2.7) | 0.65 | ||
Smoking during therapy | 105/119 (88.2) | 1.9 (0.9-4.3) | 0.10 | ||
Alcohol2 | Non-alcohol user | 600/628 (95.5) | < 0.001 | Reference | - |
Abstinence during therapy | 186/197 (94.4) | 1.0 (0.4-2.3) | 1.00 | ||
Alcohol use during therapy | 27/34 (79.4) | 4.4 (1.5-12.3) | 0.008 |
- Citation: Zhang YW, Hu WL, Cai Y, Zheng WF, Du Q, Kim JJ, Kao JY, Dai N, Si JM. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol 2018; 24(40): 4596-4605
- URL: https://www.wjgnet.com/1007-9327/full/v24/i40/4596.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i40.4596